Lupus Nephritis
📧 Sign up to get email alerts when something new happens for Lupus Nephritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-04-29FDA Approved: LUPKYNIS — Supplemental Application (Aurinia Pharma U.S., Inc.)
The FDA approved a supplemental application for LUPKYNIS (voclosporin) submitted by Aurinia Pharma U.S., Inc.
-
CLINICAL_TRIALS trial_result · 2024-04-16Clinical Trial Update: A Study of Guselkumab in Participants With Active Lupus Nephritis [Phase 2]
Phase 2 study evaluating guselkumab for active lupus nephritis was terminated, with results posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-03-08Clinical Trial Update: A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis [Phase 1, Phase 2]
Kezar Life Sciences completed a Phase 1/2 study of the immunoproteasome inhibitor KZR-616 in systemic lupus erythematosus with and without l…
-
CLINICAL_TRIALS trial_result · 2023-11-02Clinical Trial Update: Assessment of Safety and Efficacy of SGLT2is Among LN Patients [Phase 1, Phase 2]
Phase 1/2 trial updating safety and efficacy of SGLT2 inhibitors in lupus nephritis.
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis [Phase 4]
Phase 4 clinical trial comparing Mescaline Sodium enteric-coated tablets with Morte-mescaline for adult Lupus Nephritis; status currently UN…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-05-18Clinical Trial Update: Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis [Phase 3]
Phase 3 trial investigating belimumab with multi-target induction therapy for lupus nephritis; current status is unknown with remission as a…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Mesenchymal Stromal Cells (MSC´s) in Renal Lupus [Phase 2]
A Phase 2 clinical trial evaluating mesenchymal stromal cells for systemic lupus erythematosus and lupus glomerulonephritis.
-
CLINICAL_TRIALS trial_result · 2023-01-04Clinical Trial Update: Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis [Phase 3]
Phase 3 clinical trial update for Baracetinib in lupus nephritis.
-
FDA approval · 2022-12-21FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for Lannett's generic mycophenolate mofetil, authorizing its market approval as a generic immunosupp…
-
CLINICAL_TRIALS trial_result · 2022-12-14Clinical Trial Update: Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin [Phase 3]
Phase 3 trial results of voclosporin for lupus nephritis completed; assesses renal response in lupus nephritis patients.
-
CLINICAL_TRIALS trial_result · 2022-11-30Clinical Trial Update: The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN [Phase 3]
Phase 3 trial comparing human umbilical cord mesenchymal stem cells with low-dose IL-2 for treatment of systemic lupus erythematosus and lup…
-
FDA approval · 2022-11-16FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (CONCORD BIOTECH LIMITED)
FDA approved a supplemental application for mycophenolate mofetil from Concord Biotech Limited.
-
CLINICAL_TRIALS trial_result · 2022-10-17Clinical Trial Update: An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis [Phase 2]
Phase 2 trial assessing safety and effectiveness of BMS-986165 with background treatment in lupus nephritis; study terminated with results p…
-
CLINICAL_TRIALS trial_result · 2022-08-10Clinical Trial Update: MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN [Phase 4]
A Phase 4 trial update comparing mycophenolate mofetil against cyclophosphamide in induction therapy for pediatric active proliferative lupu…
-
CLINICAL_TRIALS trial_result · 2022-07-13Clinical Trial Update: An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis [Phase 2]
Phase 2 exploratory maintenance trial of BI 655064 in lupus nephritis has completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-06-21Clinical Trial Update: Comparison between2 Drugs in Lupus Nephritis [Phase 4]
Phase 4 clinical trial comparing two drugs in lupus nephritis has completed.
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis [Phase 2]
Phase 2 study of laquinimod in participants with active lupus nephritis has completed; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis [Phase 4]
Phase 4 trial update focusing on minimizing glucocorticoid use in patients with proliferative lupus nephritis.
-
CLINICAL_TRIALS trial_result · 2021-11-24Clinical Trial Update: Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis [Phase 2]
Phase 2 trial evaluating two doses of anifrolumab versus placebo in adults with active proliferative lupus nephritis completed with posted r…
-
FDA approval · 2021-10-22FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approves a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
CLINICAL_TRIALS trial_result · 2021-09-23Clinical Trial Update: Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis [Phase 4]
Phase 4 trial evaluating artesunate in combination with standard of care for active lupus nephritis to assess efficacy and safety.
-
FDA approval · 2021-08-11FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Cellcept (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
The FDA approved a supplemental application for mycophenolate mofetil submitted by Hikma Pharmaceuticals USA Inc., updating the product info…
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for mycophenolate mofetil from Teva Pharmaceuticals USA, expanding its labeling.
-
FDA approval · 2021-08-11FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for Mycophenolate mofetil from Ascend Laboratories, LLC under ANDA 203005, indicating approval of a …